Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
04
03
2022
accepted:
26
09
2022
revised:
13
09
2022
pubmed:
8
10
2022
medline:
25
11
2022
entrez:
7
10
2022
Statut:
ppublish
Résumé
The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively). We selected from the French national real-world multicentre ESME cohort (2008-2016) all patients with HER2-negative MBC with known gBRCA1/2 status at first-line chemotherapy initiation. Using multivariable Cox models, we compared the outcome (progression-free (PFS) and overall survival (OS)) of first-line PtCT and non-PtCT regimens based on the patients' gBRCA1/2 status and tumour subtype. Patients who received PtCT had more aggressive tumour features. In the multivariable analysis, first-line PtCT was associated with better adjusted PFS and OS in gBRCA1/2m carriers (N = 300), compared with non-PtCT (HR 0.54, 95% CI 0.4-0.73, P < 0.001, and HR 0.70, 95% CI 0.49-0.99, P = 0.047, respectively). Conversely, outcomes were similar in gBRCA1/2wt patients (N = 922) treated with PtCT and non-PtCT, whatever the tumour subtype. Landmark analyses at months 3 and 6 post treatment initiation supported these results. In this pre-PARP inhibitor real-world cohort, PFS and OS were better after PtCT than non-PtCT in patients with gBRCA1/2m, but not in those with gBRCA1/2wt. These results emphasise the need of early gBRCA1/2 testing in patients with MBC. NCT03275311.
Sections du résumé
BACKGROUND
The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively).
METHODS
We selected from the French national real-world multicentre ESME cohort (2008-2016) all patients with HER2-negative MBC with known gBRCA1/2 status at first-line chemotherapy initiation. Using multivariable Cox models, we compared the outcome (progression-free (PFS) and overall survival (OS)) of first-line PtCT and non-PtCT regimens based on the patients' gBRCA1/2 status and tumour subtype.
RESULTS
Patients who received PtCT had more aggressive tumour features. In the multivariable analysis, first-line PtCT was associated with better adjusted PFS and OS in gBRCA1/2m carriers (N = 300), compared with non-PtCT (HR 0.54, 95% CI 0.4-0.73, P < 0.001, and HR 0.70, 95% CI 0.49-0.99, P = 0.047, respectively). Conversely, outcomes were similar in gBRCA1/2wt patients (N = 922) treated with PtCT and non-PtCT, whatever the tumour subtype. Landmark analyses at months 3 and 6 post treatment initiation supported these results.
CONCLUSIONS
In this pre-PARP inhibitor real-world cohort, PFS and OS were better after PtCT than non-PtCT in patients with gBRCA1/2m, but not in those with gBRCA1/2wt. These results emphasise the need of early gBRCA1/2 testing in patients with MBC.
CLINICAL TRIAL NUMBER
NCT03275311.
Identifiants
pubmed: 36207609
doi: 10.1038/s41416-022-02003-1
pii: 10.1038/s41416-022-02003-1
pmc: PMC9681869
doi:
Substances chimiques
Antineoplastic Agents
0
BRCA1 Protein
0
BRCA1 protein, human
0
Platinum
49DFR088MY
Banques de données
ClinicalTrials.gov
['NCT03275311']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1963-1973Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Engel C, Fischer C. Breast cancer risks and risk prediction models. Breast Care. 2015;10:7–12.
doi: 10.1159/000376600
pubmed: 25960719
Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543–61.
doi: 10.2147/CLEP.S206949
pubmed: 31372057
pmcid: 6628947
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
doi: 10.1158/1078-0432.CCR-06-3045
pubmed: 17671126
Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010;33:637–45.
doi: 10.1097/COC.0b013e3181b8afcf
pubmed: 20023571
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–8.
doi: 10.1200/JCO.2002.09.023
pubmed: 11981002
Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73:2025–30.
doi: 10.1158/0008-5472.CAN-12-1699
pubmed: 23536562
pmcid: 3654815
Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer. 2020;126:271–80.
doi: 10.1002/cncr.32540
pubmed: 31581314
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.
doi: 10.1158/1078-0432.CCR-06-1109
pubmed: 17438091
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Cancer. 2020;129:60–70.
doi: 10.1016/j.ejca.2020.01.016
pubmed: 32135312
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–19.
doi: 10.1038/nrc1457
pubmed: 15510162
Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, et al. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem. 2008;381:240–7.
doi: 10.1016/j.ab.2008.07.007
pubmed: 18674509
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.
doi: 10.1038/nrc2342
pubmed: 18256616
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.
doi: 10.1200/JCO.2014.57.0572
pubmed: 25092775
Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497–509.
doi: 10.1016/S1470-2045(18)30111-6
pubmed: 29501363
Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29:2341–7.
doi: 10.1093/annonc/mdy460
pubmed: 30335131
Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial. JAMA Oncol. 2017;3:1378–85.
doi: 10.1001/jamaoncol.2017.1007
pubmed: 28715532
pmcid: 5710508
Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–508.
doi: 10.1093/annonc/mdy127
pubmed: 29873695
Wang D, Feng J, Xu B. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer. Future Oncol. 2019;15:2779–90.
doi: 10.2217/fon-2019-0165
pubmed: 31293180
Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. 2019;19:1065.
doi: 10.1186/s12885-019-6253-5
pubmed: 31703646
pmcid: 6839096
Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, et al. Platinum salts in patients with breast cancer: a focus on predictive factors. Int J Mol Sci. 2019;20:3390.
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628–37.
doi: 10.1038/s41591-018-0009-7
pubmed: 29713086
pmcid: 6372067
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.
doi: 10.1016/j.annonc.2020.09.010
pubmed: 32979513
Lesueur F, Mebirouk N, Jiao Y, Barjhoux L, Belotti M, Laurent M, et al. GEMO, a national resource to study genetic modifiers of breast and ovarian cancer risk in BRCA1 and BRCA2 pathogenic variant carriers. Front Oncol. 2018;8:490.
doi: 10.3389/fonc.2018.00490
pubmed: 30430080
pmcid: 6220051
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.
doi: 10.1200/JCO.1999.17.5.1474
pubmed: 10334533
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346–66.
doi: 10.1200/JCO.19.02309
pubmed: 31928404
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–22.
doi: 10.1200/JCO.2018.77.8738
pubmed: 29846122
Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Goncalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526–35.
doi: 10.1016/j.annonc.2020.08.2098
pubmed: 32828825
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.
doi: 10.1056/NEJMoa1706450
pubmed: 28578601
Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–66.
doi: 10.1093/annonc/mdz012
pubmed: 30689707
pmcid: 6503629
Dieras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:1269–82.
doi: 10.1016/S1470-2045(20)30447-2
pubmed: 32861273
Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, et al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2017;6:CD003374.
pubmed: 28643430
Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, et al. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. npj Breast Cancer. 2021;7:142.
doi: 10.1038/s41523-021-00349-y
pubmed: 34764307
pmcid: 8586340
Tung N, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). J Clin Oncol. 2020;38:1539–48.
doi: 10.1200/JCO.19.03292
pubmed: 32097092
pmcid: 8462533
Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, et al. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer. 2019;145:3359–69.
doi: 10.1002/ijc.32402
pubmed: 31087564
Delaloge S, Perol D, Courtinard C, Brain E, Asselain B, Bachelot T, et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol. 2016;27:1725–32.
doi: 10.1093/annonc/mdw260
pubmed: 27436849
Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;CD003372: https://doi.org/10.1002/14651858.CD003372.pub3 .
Vos JR, Hsu L, Brohet RM, Mourits MJ, de Vries J, Malone KE, et al. Bias correction methods explain much of the variation seen in breast cancer risks of BRCA1/2 mutation carriers. J Clin Oncol. 2015;33:2553–62.
doi: 10.1200/JCO.2014.59.0463
pubmed: 26150446
pmcid: 4979233
Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O’Shaughnessy J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33:384–94.
doi: 10.1016/j.annonc.2022.01.009
pubmed: 35093516
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.
doi: 10.1056/NEJMoa2112651
pubmed: 35139274